Published in J Control Release on March 23, 2010
More effective nanomedicines through particle design. Small (2011) 1.80
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials (2011) 1.36
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther (2012) 1.07
The shape of things to come: importance of design in nanotechnology for drug delivery. Ther Deliv (2012) 1.03
Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.02
Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm (2012) 1.00
A review on composite liposomal technologies for specialized drug delivery. J Drug Deliv (2011) 1.00
Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv (2013) 0.99
Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front Chem (2014) 0.97
In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. ACS Nano (2012) 0.97
Dilemmas in the reliable estimation of the in-vitro cell viability in magnetic nanoparticle engineering: which tests and what protocols? Nanoscale Res Lett (2012) 0.97
Engineered nanomaterial uptake and tissue distribution: from cell to organism. Int J Nanomedicine (2013) 0.95
pHLIP®-mediated delivery of PEGylated liposomes to cancer cells. J Control Release (2013) 0.95
The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials (2012) 0.94
Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells. J Microencapsul (2014) 0.92
Harnessing the power of cell-penetrating peptides: activatable carriers for targeting systemic delivery of cancer therapeutics and imaging agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 0.91
Surface engineering of liposomes for stealth behavior. Pharmaceutics (2013) 0.90
The optimization of polymalic acid peptide copolymers for endosomolytic drug delivery. Biomaterials (2011) 0.89
Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials (2014) 0.89
Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease). J Drug Deliv (2011) 0.88
Delivery of intracellular-acting biologics in pro-apoptotic therapies. Curr Pharm Des (2011) 0.87
Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release (2011) 0.87
Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept Lett (2014) 0.86
Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. Biomaterials (2014) 0.85
Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles. Int J Nanomedicine (2012) 0.83
Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells. Int J Nanomedicine (2011) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomedicine (2015) 0.82
Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J Control Release (2013) 0.81
Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. Mol Pharm (2014) 0.81
Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities. Biotechnol Adv (2013) 0.80
Effect of surface properties on liposomal siRNA delivery. Biomaterials (2015) 0.80
Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev (2015) 0.80
Branched oligopeptides form nanocapsules with lipid vesicle characteristics. Langmuir (2013) 0.79
In vitro controlled release of antigen in dendritic cells using pH-sensitive liposome-polymeric hybrid nanoparticles. Polymer (Guildf) (2015) 0.78
Enhanced cellular delivery and biocompatibility of a small layered double hydroxide-liposome composite system. Pharmaceutics (2014) 0.78
Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs. Int J Nanomedicine (2015) 0.78
Supramolecular nanoparticles generated by the self-assembly of polyrotaxanes for antitumor drug delivery. Int J Nanomedicine (2012) 0.77
Polymersome-based drug-delivery strategies for cancer therapeutics. Ther Deliv (2015) 0.77
Image-guided tumor surgery: will there be a role for fluorescent nanoparticles? Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.77
Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J Control Release (2016) 0.77
Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting. Nanomedicine (2017) 0.77
Cationic, amphiphilic copolymer micelles as nucleic acid carriers for enhanced transfection in rat spinal cord. Acta Biomater (2016) 0.76
Lipid nanoparticles for gene delivery. Adv Genet (2014) 0.76
Stealth, biocompatible monoolein-based lyotropic liquid crystalline nanoparticles for enhanced aloe-emodin delivery to breast cancer cells: in vitro and in vivo studies. Int J Nanomedicine (2016) 0.76
Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells. Int J Nanomedicine (2016) 0.76
Materials design at the interface of nanoparticles and innate immunity. J Mater Chem B Mater Biol Med (2016) 0.76
Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo. Int J Nanomedicine (2016) 0.75
Ultrasound effects on brain-targeting mannosylated liposomes: in vitro and blood-brain barrier transport investigations. Drug Des Devel Ther (2015) 0.75
Development, Optimization, and Characterization of PEGylated Nanoemulsion of Prostaglandin E1 for Long Circulation. AAPS PharmSciTech (2015) 0.75
Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. Int J Nanomedicine (2015) 0.75
Composite nanoparticles for gene delivery. Adv Genet (2014) 0.75
The influence of surface charge on serum protein interaction and cellular uptake: studies with dendritic polyglycerols and dendritic polyglycerol-coated gold nanoparticles. Int J Nanomedicine (2017) 0.75
Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery In Vitro and In Vivo. Theranostics (2017) 0.75
Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics (2017) 0.75
Capillary collagen as the physical transport barrier in drug delivery to tumor microenvironment. Tissue Barriers (2015) 0.75
α-((4-Cyanobenzoyl)oxy)-ω-methyl poly(ethylene glycol): a new stabilizer for silver nanoparticles. Beilstein J Nanotechnol (2017) 0.75
Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery. ACS Appl Mater Interfaces (2016) 0.75
Precision spherical nucleic acids for delivery of anticancer drugs. Chem Sci (2017) 0.75
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A (2007) 3.26
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release (2003) 2.07
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta (2009) 1.94
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
To PEGylate or not to PEGylate, that is not the question. J Control Release (2010) 1.04
Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. J Drug Target (2000) 1.00
CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. J Control Release (2009) 0.98
Well-defined block copolymers for gene delivery to dendritic cells: probing the effect of polycation chain-length. J Control Release (2009) 0.97
Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J Control Release (2009) 0.94
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer (2004) 2.31
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta (2009) 1.94
Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol (2010) 1.81
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release (2011) 1.72
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Non-viral is superior to viral gene delivery. J Control Release (2007) 1.54
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci (2006) 1.46
Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res (2010) 1.38
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials (2006) 1.30
Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem (2010) 1.28
Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc (2010) 1.27
Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol (2007) 1.24
A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano (2013) 1.22
Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine (2012) 1.21
Development of non-viral vectors for systemic gene delivery. J Control Release (2002) 1.21
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther (2005) 1.19
Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther (2010) 1.17
Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther (2011) 1.15
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm (2005) 1.11
Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci (2010) 1.10
Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev (2005) 1.10
A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother (2007) 1.08
The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm (2011) 1.08
Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release (2013) 1.08
HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J Control Release (2004) 1.08
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther (2012) 1.07
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07
LPD nanoparticles--novel nonviral vector for efficient gene delivery. Methods Mol Med (2002) 1.03
Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release (2008) 1.03
Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm (2010) 1.02
Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. Mol Ther (2005) 1.01
Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother (2005) 1.01
Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method? Pharm Res (2012) 1.00
Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm (2012) 1.00
Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials (2013) 0.99
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther (2013) 0.98
Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J Invest Dermatol (2004) 0.98
Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano (2014) 0.97
Recent advances in intravesical drug/gene delivery. Mol Pharm (2006) 0.97
Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol (2006) 0.96
The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials (2012) 0.94
Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol (2004) 0.93
Noninvasive gene delivery to the liver by mechanical massage. Hepatology (2002) 0.92
Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo. Mol Ther (2005) 0.92
A syringe electrode device for simultaneous injection of DNA and electrotransfer. Mol Ther (2002) 0.92
Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res (2004) 0.92
Controlled gene delivery system based on thermosensitive biodegradable hydrogel. Pharm Res (2003) 0.91
Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano (2014) 0.91
Non-immunostimulatory nonviral vectors. FASEB J (2004) 0.91
Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. Urology (2003) 0.91
Lipid-protamine-DNA-mediated antigen delivery. Curr Drug Deliv (2005) 0.90
Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials (2013) 0.90
Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs (2008) 0.90
Activity of different phospholipids in attenuating hyperactivity in bladder irritation. BJU Int (2007) 0.90
Recent advances in non-viral gene delivery. Adv Genet (2005) 0.89
Enhanced cutaneous gene delivery following intradermal injection of naked DNA in a high ionic strength solution. Mol Ther (2002) 0.89
Non-viral vector as vaccine carrier. Adv Genet (2005) 0.88
Thermosensitive hydrogel as a Tgf-beta1 gene delivery vehicle enhances diabetic wound healing. Pharm Res (2003) 0.88
Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol Pharm (2008) 0.88
Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors. Mol Ther (2007) 0.87
Mechanism of in vivo DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved. J Gene Med (2006) 0.87
Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology (2003) 0.87
Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release (2011) 0.87
Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer Immunol Immunother (2011) 0.86
Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv (2008) 0.86
Mechanism of naked DNA clearance after intravenous injection. J Gene Med (2007) 0.86
Recent Advances in Non-viral Gene Delivery. Adv Genet (2005) 0.85
Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm (2010) 0.85
Mechanism of liver gene transfer by mechanical massage. Mol Ther (2004) 0.84
Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem (2012) 0.84
Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm Res (2004) 0.84
Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. Mol Pharm (2006) 0.84
Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther (2002) 0.84
How does the cell overcome LCP nanoparticle-induced calcium toxicity? Mol Pharm (2013) 0.83
Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res (2002) 0.83
Cancer immunotherapy and nanomedicine. Pharm Res (2010) 0.83
Gene transfer to subdermal tissues via a new gene gun design. Hum Gene Ther (2003) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
Novel nonviral vectors target cellular signaling pathways: regulated gene expression and reduced toxicity. J Pharmacol Exp Ther (2007) 0.82
Smart polymeric nanoparticles for cancer gene delivery. Mol Pharm (2015) 0.82
Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. J Control Release (2013) 0.81
Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther (2003) 0.81
Cationic liposome-protamine-DNA complexes for gene delivery. Methods Enzymol (2003) 0.81
Intradermal injection of transforming growth factor-beta1 gene enhances wound healing in genetically diabetic mice. Pharm Res (2003) 0.81
Targeted delivery of EV peptide to tumor cell cytoplasm using lipid coated calcium carbonate nanoparticles. Cancer Lett (2012) 0.81
Lipid-based vectors for siRNA delivery. J Drug Target (2012) 0.81
Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine (Lond) (2010) 0.81